Fair Value Calculator Fair Value Calculator
EN DE

Koninklijke Philips N.V (1PHIA) Fair Value & Analysis

Healthcare · IT · Market cap €23.6B

KP Koninklijke Philips N.V 1PHIA · MI
Price€24.31
Fair Value€9.97
Upside-59.0%
Quality61/100
Watch Koninklijke Philips N.V for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range €8.04 – €12.26

Fair value as of: Jul 3, 2026

From 24 valuation models · updated 2 days ago

Share price +12.7% over the past month.

Price vs Fair Value (12 months)

€26.25 €19.26 Fair Value €9.97 Jul 2025 Jul 2026

12‑month range €19.26 – €26.25 · fair‑value band €8.04 – €12.26 · the €24.31 price screens above the €9.97 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Koninklijke Philips N.V (1PHIA) currently trades at €24.31, while our model-based Fair Value estimate is €9.97 — implying the stock looks roughly 59.0% overvalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, Koninklijke Philips N.V generated revenue of €17.6B at a net margin of 5.5%. Revenue declined 4.7% year over year. It earns a return on equity of 8.4%. Net debt stands at €4.1B. Fundamentals as of Jul 3, 2026

Our scenario range runs from €8.04 (bear case) to €12.26 (bull case); at €24.31, the current price sits above that range. The share trades about 10% below its 52-week high and 26% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside — at -59%, 1PHIA screens richer than that median.

Key figures & financial health

Revenue (TTM) €17.6B
Revenue growth (YoY) -4.7%
Net margin 5.5%
Return on equity 8.4%
Free cash flow €504M FY2025
P/E ratio 24.1
More key figures
Operating margin 6.2%
EPS (TTM) €1.01
Dividend yield 3.5%
EPS growth (YoY) +97.2%
Net debt €4.1B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

About the company

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

Koninklijke Philips N.V reported revenue of €17.8B in FY2025 versus €17.8B in FY2022, a compound +0.0%/yr. Reported net income was €895M in FY2025.

Revenue +0.0%/yr
FY22 €17.8B
FY23 €18.2B
FY24 €18.0B
FY25 €17.8B
Net income
FY22 −€1.6B
FY23 −€466M
FY24 −€702M
FY25 €895M

Is 1PHIA fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Koninklijke Philips N.V Fair Value". https://www.fairvalue-calculator.com/stock/1PHIA

Recent news

External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT 1,600 MXN 82.40 MXN -95%
Stryker Corporation S1YK34 R$79.21 R$43.74 -45%
Medtronic plc MDT $81.67 $60.02 -27%
Boston Scientific Corporation B1SX34 R$248.75 R$221.81 -11%
Edwards Lifesciences Corporation EW $85.98 $41.02 -52%
Siemens Healthineers AG SEMHF $39.95 $44.36 +11%
GE HealthCare Technologies Inc GEHC $61.99 $48.34 -22%
DexCom, Inc DXCM $69.07 $65.56 -5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥143.50 ¥111.50 -22%
STERIS plc STE $200.40 $176.96 -12%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Koninklijke Philips N.V (1PHIA) undervalued?
As of Jul 3, 2026, our model estimates a fair value of €9.97 versus a price of €24.31 — about −59% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1PHIA?
Our model-based fair value for Koninklijke Philips N.V is €9.97 (as of Jul 3, 2026), built from audited fundamentals. The current price is €24.31.
What is the quality score of 1PHIA?
Koninklijke Philips N.V has a Quality Score of 61/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Koninklijke Philips N.V (1PHIA)?
Koninklijke Philips N.V reported trailing-twelve-month revenue of about €17.6B (latest available figure, as of Jul 3, 2026).
What is the net profit margin of 1PHIA?
The net profit margin of Koninklijke Philips N.V is about 5.5%, meaning it keeps roughly 5.5% of revenue as net income. Based on the latest reported figures.
Does Koninklijke Philips N.V pay a dividend?
Koninklijke Philips N.V currently shows a dividend yield of about 3.50% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.